FDA Approves Nasacort HFA for Allergic RhinitisNasacort HFA (triamcinolone acetonide) is a dry-aerosol intranasal corticosteroid formulation containing hydrofluoroalkane (HFA). It replaces Nasacort Nasal Inhaler, which along with other nasal inhalers containing CFC’s, was taken off the market to comply with Environmental Protection Agency (EPA) and FDA requirements intended to protect the ozone layer. Nasacort HFA Nasal Aerosol is indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and children age 6 and older.
Posted: April 2004
- FDA Approves Sanofi's Nasacort Allergy 24HR for Over-the-Counter Use - October 11, 2013
- FDA Approves Nasacort AQ Nasal Spray for Children Aged 2-5 years old - September 23, 2008